Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2017; 17(4):275-278
DOI: 10.5428/pcar20170409
Development of chimeric antigen receptor T cell products and challenges encountered in clinical application
1. WANG Chong(Shanghai Center for Drug Evaluation and Inspection,Shanghai 201203,China [email protected])
ABSTRACT  Chimeric antigen receptor T cell(CAR-T) products have achieved obvious effects in tumor immunotherapy.CAR-T cell therapy has shown high objective response rates,especially in the patients with B lymphocyte malignance.The feasibility of industrial production,choice of viral vector,challenges encountered in clinical application and strategies for the development of CAR-T cell products were reviewed in the paper.
Welcome to PCAR! You are the number 124 reader of this article!
Please cite this article as:
WANG Chong,. Development of chimeric antigen receptor T cell products and challenges encountered in clinical application[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2017; 17(4): 275-278.
References:
1. Kalos M,Levine B L,Porter D L,et al.T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia[J].Sci Transl Med,2011,3(95):95ra73.
2. Porter D L,Hwang W T,Frey N V,et al.Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia[J].Sci Transl Med,2015,7(303):303ra139.
3. Singh N,Perazzelli J,Grupp S A,et al.Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies[J].Sci Transl Med,2016,8(320):320ra3.
4. Przybylowski M,Hakakha A,Stefanski J,et al.Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories[J].Gene Ther,2006,13(1):95-100.
5. Levine B,Miskin J,Wonnacott K,et al.Global manufacturing of CAR T cell therapy[J].Mol Ther:Methods Clin Dev,2017,4(3):92-101.
6. Smith A J,Oertle J,Warren D,et al.Chimeric antigen receptor (CAR) T cell therapy for malignant cancers:summary and perspective[J].J Cell Immunother,2016,2(8):59-68.
7. Varmus H E,Quintrell N,Ortiz S.Retroviruses as mutagens:insertion and excision of a nontransforming provirus alter expression of a resident transforming provirus[J].Cell,1981,25(1):23-36.
8. Shen-Ong G L,Potter M,Mushinski J F,et al.Activation of the c-myb locus by viral insertional mutagenesis in plasmacytoid lymphosarcomas[J].Science,1984,226(4678):1077-1080.
9. Scholler J,Brady T L,Binder-Scholl G,et al.Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells[J].Sci Transl Med,2012,4(132):132ra53.
10. The Food and Drug Administration.Briefing document-testing for replication competent retrovirus (RCR)/lentivirus (RCL) in retroviral and lentiviral vector-based gene therapy products-revisiting current FDA recommendations.(2016-04-12)[2017-03-24].http://www.docin.com/p-1770046840.html.
11. Maude S L,Teachey D T,Porter D L,et al.CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia[J].Blood,2015,125(26):4017-4023.
12. Maude S L,Barrett D,Teachey D T,et al.Managing cytokine release syndrome associated with novel T cell-engaging therapies[J].Cancer J,2014,20(2):119-122.
13. SHI Huan,LIU Lin,WANG ZheHai.Improving the efficacy and safety of engineered T cell therapy for cancer[J].Cancer Lett,2013,328(2):191-197.
14. Sagoo P,Ali N,Garg G,et al.Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells[J].Sci Transl Med,2011,3(83):83ra42.
15. Lee D W,Kochenderfer J N,Stetler-Stevenson M,et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial[J].Lancet,2015,385(14):517-528.
16. Maude S L,Frey N,Shaw P A,et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med,2014,371(16):1507-1517.
17. Jackson H J,Brentjens R J.Overcoming antigen escape with CAR T-cell therapy[J].Cancer Discov,2015,5(12):1238-1240.
18. Riches J C,Davies J K,McClanahan F,et al.T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production[J].Blood,2013,121(9):1612-1621.
19. Curran K J,Seinstra B A,Nikhamin Y,et al.Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression[J].Mol Ther,2015,23(4):769-778.
20. Brudno J N,Somerville R P T,Shi V,et al.Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease[J].J Clin Oncol,2016,34(10):1112-1121.
21. Fraietta J A,Beckwith K A,Patel P R,et al.Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia[J].Blood,2016,127(9):1117-1127.
22. Sadelain M,Brentjens R,Riviere I.The basic principles of chimeric antigen receptor(CAR) design[J].Cancer Discov,2013,3(4):388-398.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:[email protected]
·技术支持:中国康网
管理员入口